Eftilagimod alfa
- Generic Name
- Eftilagimod alfa
- Drug Type
- Biotech
- CAS Number
- 1800476-36-1
- Unique Ingredient Identifier
- SJ82PK3HWA
- Background
Eftilagimod alfa is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma).
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
Phase 3
Recruiting
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Immutep S.A.S.
- Target Recruit Count
- 756
- Registration Number
- NCT06726265
- Locations
- 🇧🇪
Algemeen Ziekenhuis Maria Middelares, Gent, Belgium
🇧🇪Clinique et Maternité Sainte-Elisabeth, Namur, Belgium
🇧🇬Multiprofile Hospital for Active Treatment - Dobrich AD, Dobrich, Bulgaria
Feasibility and Safety of IMP321 (eftilagimod Alpha) for Advanced Stage Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid TumorsPeritoneal CarcinomatosisNSCLC AdenocarcinomaUrothelial Carcinoma
- Interventions
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Target Recruit Count
- 110
- Registration Number
- NCT03252938
- Locations
- 🇩🇪
Helios Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Universitätsklinikum Essen, Essen, Germany
🇩🇪Agaplesion Markus Krankenhaus Frankfurter Diakonie Kliniken gGmbH, Frankfurt, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath